|
|
|
|
|
Physostigmine
drug data and news
Physostigmine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Physostigmine | ||
| Brand Names/Synonyms | Antilirium; Cogmine Eserine; Erserine; Eserine; Eserine Salicylate; Eserine Sulfate; Eserolein, Methylcarbamate; Esromiotin; Ezerin; Fysostigmin; Isopto Eserine; PHYSOSTIGMINE 9599; Physostigmine; Physostol; Salicylate | ||
| Indication | For the treatment of Glaucoma | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia. | ||
| Mechanism Of Action | By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors. | ||
| Physostigmine News (When available) |
Management of Acute Undifferentiated Agitation in the Emergency ... Apr 26, 2006 Full Social Lives May Protect Against Alzheimer's Apr 29, 2006 | ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Antiglaucomic Agents; Ophthalmics; Parasympathomimetics; ATC:S01EB05; ATC:V03AB19 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Physostigmine: No information provided. | ||
| Toxicity | Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, eye pain | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C15H21N3O2 | ||
| Molecular Weight | 275.346 g/mol | ||
| Smiles String | CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C | ||
| Melting Point | 105.5 °C | ||
| Water Solubility | 7760 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 2.495 | ||
| Isoelectric Point | 6.12 | ||
| Biotransformation | Quickly hydrolyzed by cholinesterases | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Physostigmine.html http://www.rxlist.com/cgi/generic3/physostigmine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00406 | ||
| CAS Registry Number | 57-47-6 | ||
| KEGG Compound ID | C06535 | ||
| PubChem ID | SID:65991 | ||
| PharmGKB ID | PA450957 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 344931 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |